Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients

Alberca, Ricardo Wesley; Yendo, Tatiana Mina; Ramos, Yasmim Álefe Leuzzi; Fernandes, Iara Grigoletto; Oliveira, Lucas Ferrari de; Teixeira, Franciane Mouradian Emidio; Beserra, Danielle Rosa; Oliveira, Emily Araujo de; Gozzi-Silva, Sarah Cristina; Andrade, Milena Mary de Souza; Branco, Anna Cláudia Calvielli Castelo; Pietrobon, Anna Julia; Pereira, Newton Lindolfo; Brito, Cyro Alves de; Orfali, Raquel Leão; Aoki, Valéria; Duarte, Alberto José da Silva; Benard, Gil; Sato, Maria Notomi

doi:10.4269/ajtmh.20-1185

Cited by 36 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The infection caused by SARS-CoV-2 can lead to the development of a severe pulmonary and systemic disease named COVID-19 ( Alberca et al, 2020c ). Previous reports have identified that COVID-19 is often more severe in the elderly and individuals with comorbidities such as obesity, hypertension, diabetes Mellitus, other co-infections ( Alberca, 2020 ; Alberca et al, 2020a , d , f ; Castelo Branco et al, 2020 ; Shaw et al, 2020 ). Those patients generally present an increase in COVID-19-associated inflammatory markers, such as d-dimer, leukocytes count, neutrophil count, neutrophil-to-lymphocyte (NTL) ratio, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and c-reactive protein (CRP) ( Wolff et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

The severe respiratory and systemic disease named coronavirus disease-2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, the COVID-19 pandemic presents a huge social and health challenge worldwide. Many different risk factors are associated with disease severity, such as systemic arterial hypertension, diabetes mellitus, obesity, older age, and other co-infections. Other respiratory diseases such as chronic obstructive pulmonary disease (COPD) and smoking are common comorbidities worldwide. Previous investigations have identified among COVID-19 patients smokers and COPD patients, but recent investigations have questioned the higher risk among these populations. Nevertheless, previous reports failed to isolate smokers and COPD patients without other comorbidities. We performed a longitudinal evaluation of the disease course of smokers, former smokers, and COPD patients with COVID-19 without other comorbidities, from hospitalization to hospital discharge. Although no difference between groups was observed during hospital admission, smokers and COPD patients presented an increase in COVID-19-associated inflammatory markers during the disease course in comparison to non-smokers and former smokers. Our results demonstrated that smoking and COPD are risk factors for severe COVID-19 with possible implications for the ongoing pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The CD patients presented an increase in COVID-19 laboratory hallmarks and a rapid disease progression. Despite the efforts of the health staff, both patients died [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…Most patients with the disease have mild-to-moderate symptoms; however, approximately 15% develop severe pneumonia, while approximately 5% develop acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure [ 2 ]. Lymphopenia is a recurrent feature in these patients, with a significant reduction in CD4+ T cells, CD8+ T cells, B cells, and natural killer (NK) cells [ 3 ], increasing the susceptibility of patients to severe illness and co-infection [ 4 ]. In fact, co-infections are associated with worsening of the clinical condition [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report

Gozzi-Silva

Benard²,

Alberca³

et al. 2021

TropicalMed

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2, Trypanosoma cruzi, and cytomegalovirus (CMV) dissemination, from the first day of hospitalization due to COVID-19 in the intensive care unit (ICU) until the death of the patients.

show abstract

“…Since November 2019, SARS-CoV-2 has infected over 80 million people and killed over 1.5 million people worldwide, being declared a pandemic by the World Health Organization[ 4 ]. Several comorbidities have been postulated as risk factors for severe COVID-19, such as high age[ 5 ], smoking, chronic obstructive pulmonary disease[ 6 ], obesity[ 7 ], pregnancy[ 8 ], and co-infections[ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Coronavirus disease–2019 and the intestinal tract: An overview

Alberca

Solis-Castro

et al. 2021

WJG

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can progress to a severe respiratory and systemic disease named coronavirus disease–2019 (COVID-19). The most common symptoms are fever and respiratory discomfort. Nevertheless, gastrointestinal infections have been reported, with symptoms such as diarrhea, nausea, vomiting, abdominal pain, and lack of appetite. Importantly, SARS-CoV-2 can remain positive in fecal samples after nasopharyngeal clearance. After gastrointestinal SARS-CoV-2 infection and other viral gastrointestinal infections, some patients may develop alterations in the gastrointestinal microbiota. In addition, some COVID-19 patients may receive antibiotics, which may also disturb gastrointestinal homeostasis. In summary, the gastrointestinal system, gut microbiome, and gut-lung axis may represent an important role in the development, severity, and treatment of COVID-19. Therefore, in this review, we explore the current pieces of evidence of COVID-19 gastrointestinal manifestations, possible implications, and interventions.

show abstract

Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients

Cited by 36 publications

References 24 publications

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

COVID-19 Disease Course in Former Smokers, Smokers and COPD Patients

SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report

Coronavirus disease–2019 and the intestinal tract: An overview

Contact Info

Product

Resources

About